Evotec

(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release →

(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release →

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release →

(IN BRIEF) Evotec SE announced that Dr. Craig Johnstone, the company’s Chief Operating Officer, will step down on 31 December 2024. Dr. Johnstone joined Evotec in 2012 and held various leadership roles, including Global Head of Integrated Drug Discovery and … Read the full press release →

(IN BRIEF) Evotec SE has sold its chemical API-focused manufacturing site, Evotec DS GmbH, to Monacum Partners as part of its “Priority Reset” strategy to focus on core growth areas. The Halle/Westphalia-based facility, now renamed DAPIN GmbH, will continue its … Read the full press release →

(IN BRIEF) Evotec SE has made significant progress in its strategic partnership with Bristol Myers Squibb, focused on developing a molecular glue-based therapy pipeline. This success has led to $75 million in milestone payments to Evotec. The partnership, which began … Read the full press release →

(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ … Read the full press release →

(IN BRIEF) Evotec SE announces a partnership with Inserm, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic markers in obesity and metabolic diseases. The collaboration, centered around the ABOS/DIABOMICS study led by Lille University Hospital, … Read the full press release →

(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release →

(IN BRIEF) Evotec Biologics, the biologics arm of Evotec SE, has introduced its proprietary J.CHO™ High Expression System for antibody expression. J.CHO™ optimizes biotherapeutic production processes by providing higher productivity and quality for complex antibody formats. Engineered from Chinese hamster … Read the full press release →

(IN BRIEF) Evotec SE announces the appointment of Aurélie Dalbiez as their new Chief People Officer (CPO), effective June 15, 2024. Joining the Management Board, Aurélie brings over 25 years of international Human Resources leadership experience, previously serving as the … Read the full press release →

(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release →

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release →

(IN BRIEF) Evotec and Claris Ventures have formed a strategic partnership to accelerate the progress of biotech ventures in Claris’s portfolio into clinical trials. This collaboration allows Claris’s portfolio companies, focused on biotech ventures nearing clinical trials, streamlined access to … Read the full press release →